Physician profile
Carmen Buggey
NPI 1265976658
$1,438.27
in general payments reported to CMS, 2019-2025
21 companies · $671 in 2025
The $671 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $419 · 2023: $61.81 · 2024: $14.93 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $312.08 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $209.19 | 2021-2023 | Jardiance, Emgality |
| Atricure, INC. | $146.12 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Abbott Laboratories | $113.66 | 2022-2025 | Mitraclip, Freestyle Libre 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.85 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $77.30 | 2025 | Camzyos |
| Abbvie INC. | $72.02 | 2021-2023 | |
| Novo Nordisk INC | $69.43 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.31 | 2021-2022 | |
| Glaxosmithkline, LLC. | $50.67 | 2022 | |
| Heartflow, INC. | $48.18 | 2025 | |
| Dexcom, INC. | $29.91 | 2022 | |
| Boston Scientific Corporation | $26.33 | 2025 | Cds - Mct/Cem Monitoring |
| Novartis Pharmaceuticals Corporation | $23.95 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.58 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $18.94 | 2025 | Telepatch Cardiac Monitor |
| Astrazeneca Pharmaceuticals Lp | $16.10 | 2025 | Farxiga |
| Esperion Therapeutics, INC. | $13.78 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $13.75 | 2025 | |
| Pfizer INC. | $13.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Buggey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.